Canaccord Genuity Reiterates $25.00 Price Target for Savara (SVRA)
A number of other brokerages have also weighed in on SVRA. BidaskClub raised shares of Savara from a hold rating to a buy rating in a research note on Wednesday, June 20th. Zacks Investment Research raised shares of Savara from a sell rating to a hold rating in a research note on Saturday, June 23rd. HC Wainwright reaffirmed a buy rating and issued a $22.00 price target on shares of Savara in a research note on Friday, August 10th. Roth Capital assumed coverage on shares of Savara in a research note on Monday, August 13th. They set a neutral rating and a $12.00 target price for the company. Finally, ValuEngine raised shares of Savara from a strong sell rating to a sell rating in a research note on Wednesday, May 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $22.94.
Shares of NASDAQ:SVRA opened at $10.60 on Tuesday. The company has a market capitalization of $343.52 million, a PE ratio of -6.02 and a beta of -0.24. Savara has a twelve month low of $5.07 and a twelve month high of $17.19. The company has a quick ratio of 10.30, a current ratio of 10.30 and a debt-to-equity ratio of 0.16.
In related news, CFO David L. Lowrance sold 5,275 shares of the stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $12.08, for a total transaction of $63,722.00. Following the completion of the sale, the chief financial officer now directly owns 23,080 shares of the company’s stock, valued at $278,806.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jaakko Taneli Jouhikainen sold 2,638 shares of the stock in a transaction that occurred on Friday, June 8th. The shares were sold at an average price of $12.11, for a total transaction of $31,946.18. Following the sale, the insider now directly owns 207,688 shares of the company’s stock, valued at $2,515,101.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,055 shares of company stock valued at $569,209. Company insiders own 6.10% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in Savara by 188.6% during the second quarter. BlackRock Inc. now owns 2,006,238 shares of the company’s stock valued at $22,711,000 after purchasing an additional 1,310,969 shares during the last quarter. Lyon Street Capital LLC lifted its position in shares of Savara by 85.0% in the 1st quarter. Lyon Street Capital LLC now owns 1,441,984 shares of the company’s stock valued at $13,266,000 after acquiring an additional 662,430 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Savara by 1.4% in the 2nd quarter. Jennison Associates LLC now owns 794,234 shares of the company’s stock valued at $8,991,000 after acquiring an additional 10,612 shares in the last quarter. Millennium Management LLC lifted its position in shares of Savara by 1,161.8% in the 1st quarter. Millennium Management LLC now owns 522,897 shares of the company’s stock valued at $4,811,000 after acquiring an additional 481,456 shares in the last quarter. Finally, Brown Advisory Inc. lifted its position in shares of Savara by 187.8% in the 1st quarter. Brown Advisory Inc. now owns 406,751 shares of the company’s stock valued at $3,742,000 after acquiring an additional 265,402 shares in the last quarter. 42.40% of the stock is owned by institutional investors and hedge funds.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Article: Investing in Dividend Stocks
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.